Abbott (NYSE:ABT) faces a proposed class action lawsuit related to alleged tracking tools used with its FreeStyle Libre ...

Abbott Laboratories' (NYSE: ABT) business has been a bit of a roller coaster. The pandemic disrupted its medical device ...

Abbott’s FreeStyle Libre devices involve a small sensor applied ... Abbott’s industry partners seem to view these collaborations in the same way. Que Dallara, president of Medtronic Diabetes ...

ABT made its CGM system Lingo available in the United States. The system can be used by consumers aged 18 years and older who ...

Designed to track glucose in real time, Lingo is based on Abbott's FreeStyle Libre CGM technology ... It is also accessible in the UK. Per a Grand View Research report, the global CGM devices ...

So, while you should always follow the fundamentals of healthy living – like exercising and eating a balanced diet – ...

Piper Sandler initiated coverage on Abbott Laboratories (NYSE: ABT) with an "overweight" rating and a price target of $131 ...

RHHBY's Accu-Chek Smartguide will provide several predictive features aimed at enhancing patient safety. However, the device ...

The results were further supported by data from continuous glucose monitoring (CGM; Freestyle Libre Pro iQ), which was used by approximately 80% of patients in the study and reported in a separate ...

Within medical devices, diabetes sales have been seeing double-digit growth lately, led by FreeStyle Libre. The nutritional ... appropriately priced, in our view. While ABT may outperform MDT ...

Restricting eating to an 8-hour window improves blood glucose no matter whether the eating window is early or late in the day in people at risk for type 2 diabetes.

again accusing Abbott of patent infringement for its FreeStyle Libre 2 device. This sparked a flurry of litigation between the parties in the US. Since 2021, Abbott and DexCom have been involved ...